Watson Pharmaceuticals has announced that a lot of its Propafenone HCL 225 mg Tablets sold in 100-count bottles in the US is being recalled as some tablets could contain higher levels of the active ingredient than is specified.
The tablets which may contain increased levels of the pharmaceutical ingredient were shipped to consumers between October 15th and November 26th 2008, while no other strengths or lots were affected.
Propafenone is used to treat cardiac arrhythmias, otherwise known as irregular heartbeats, and feature a narrow therapeutic index, meaning that some patients who are particularly sensitive to small variations in dose may suffer from possibly serious side effects.
"Anyone who has 225 mg Propafenone HCL tablets should check the bottle for the lot number and expiration date to see if they have tablets being recalled," Watson advised.
Earlier this month, Watson announced it had reached a settlement with with Elan Corporation regarding outstanding patent litigation related to the former's generic version of Naprelan tablets
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment